The Claim

Among adults with type 2 diabetes and established atherosclerotic cardiovascular disease, weekly subcutaneous tirzepatide (up to 15 mg) is noninferior to dulaglutide (1.5 mg) in reducing the composite risk of death from cardiovascular causes, myocardial infarction, or stroke over a median follow-up of 4.0 years, with a hazard ratio of 0.92 (95.3% CI, 0.83 to 1.01), indicating no increased risk despite greater weight and glycemic improvements.

Source: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
82score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

In adults with type 2 diabetes and heart disease, a weekly injection of tirzepatide reduces the risk of heart-related death, heart attack, or stroke just as effectively as another drug called dulaglutide, even though tirzepatide leads to greater weight loss and better blood sugar control.

See the scientific wording

Among adults with type 2 diabetes and established atherosclerotic cardiovascular disease, weekly subcutaneous tirzepatide (up to 15 mg) is noninferior to dulaglutide (1.5 mg) in reducing the composite risk of death from cardiovascular causes, myocardial infarction, or stroke over a median follow-up of 4.0 years, with a hazard ratio of 0.92 (95.3% CI, 0.83 to 1.01), indicating no increased risk despite greater weight and glycemic improvements.

Why this might work

Tirzepatide helps the body use insulin better and reduces hunger, leading to lower blood sugar and weight loss. This lowers fat buildup in blood vessels, reduces inflammation, and eases pressure on the heart, which together prevent heart attacks, strokes, and heart-related deaths.

Supported mechanismbased on 1 study

What the research says

1 study
  1. Study: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.

    In people with type 2 diabetes and heart disease, tirzepatide didn't cause more heart attacks, strokes, or heart-related deaths than dulaglutide, even though it helped them lose more weight and control blood sugar better.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.